Here, we observed that PSMA PET performed in patients with recurrent or de-novo metastatic RCC changed management in 29% (14/48), which was numerically higher for patients with recurrent than de-novo metastatic disease (31% vs 23%, p=0.73). This evidence concerns the gene FOLH1 and metastatic neoplasm.